FDA actions in brief, March 2009 (Gelnique, RiaSTAP, Kapidex)

Oxybutynin gel 10% (Gelnique, Watson) was approved for the topical treatment of overactive bladder.

Fibrinogen concentrate (human) (RiaSTAP, CSL Behring) was approved for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

Dexlansoprazole delayed-release capsules (Kapidex, Takeda) were approved for the once-daily treatment of heartburn associated with symptomatic nonerosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE), and the maintenance of healed EE.